Estrogen Therapy Contraindicated in Women > 35 Years Who Smoke

Cardiovascular and Thrombotic Risk Magnitude

Smoking combined with estrogen therapy raises the relative risk of myocardial infarction to 12.5‑fold in women who smoke more than 20 cigarettes per day (Annales d’endocrinologie) 4.
The combination produces a synergistic thrombotic risk through dose‑dependent elevation of plasminogen activator inhibitor‑1 (PAI‑1) and altered hepatic estrogen metabolism (Annales d’endocrinologie) 4.
Risk of cardiovascular and venous thromboembolic disease escalates exponentially with age when estrogen and smoking are co‑administered (American College of Endocrinology & American Association of Clinical Endocrinologists) 1.
The majority of coronary and cerebrovascular events occur in women aged 35‑40, with smoking identified as a key contributor (Annales d’endocrinologie) 4.

Cerebrovascular accidents (strokes) increase in an age‑dependent manner among estrogen users (American College of Endocrinology & American Association of Clinical Endocrinologists) 1.
Venous thromboembolism risk is markedly elevated irrespective of smoking intensity (American College of Endocrinology & American Association of Clinical Endocrinologists) 2.

Age ≥ 35 years with any smoking history (especially ≥15 cigarettes/day) (Praxis Medical Insights) 3.
Prior stroke or transient ischemic attack (Praxis Medical Insights) 5.
History of venous thromboembolism (Annales d’endocrinologie) 4.
Uncontrolled hypertension (≥160/100 mm Hg) (Annales d’endocrinologie) 4.
Known thrombophilia (Praxis Medical Insights) 5.

Exclude all estrogen‑containing products (oral, transdermal, vaginal) immediately (Praxis Medical Insights) 3.
Prioritize aggressive smoking cessation as the primary intervention (American College of Endocrinology & American Association of Clinical Endocrinologists) 1.
When menopausal symptoms require therapy, use non‑hormonal agents such as clonidine, selective serotonin reuptake inhibitors, or gabapentin (American College of Endocrinology & American Association of Clinical Endocrinologists) 1.
Low‑dose vaginal estrogen may be considered only for isolated genitourinary symptoms, recognizing minimal systemic absorption (American College of Endocrinology & American Association of Clinical Endocrinologists) 1.

Comprehensive cardiovascular risk profiling (lipids, smoking intensity, diabetes, family history) (American College of Endocrinology & American Association of Clinical Endocrinologists) 2.
Document daily cigarette consumption, as risk rises proportionally (Annales d’endocrinologie) 4.
Screen for additional thrombotic risk factors (e.g., hypertension, obesity, thrombophilia) (Annales d’endocrinologie) 4.

Do not prescribe low‑dose estrogen formulations under the assumption they are safer; the contraindication applies to all doses and routes (Praxis Medical Insights) 3.
Do not consider transdermal estradiol an exception for smokers > 35 years; cardiovascular and thrombotic risks remain unacceptably high (American College of Endocrinology & American Association of Clinical Endocrinologists) 1.
Do not assume light smoking (<15 cigarettes/day) makes estrogen acceptable; any smoking constitutes a contraindication (Praxis Medical Insights) 3.

Women who have quit smoking: estrogen therapy may be classified as Category 2 (generally usable with careful follow‑up) for those >45 years, after thorough cardiovascular assessment (Praxis Medical Insights) 3.
Osteoporosis prevention: prioritize approved non‑estrogen agents (bisphosphonates, denosumab, selective estrogen receptor modulators) before considering hormone therapy (American College of Endocrinology & American Association of Clinical Endocrinologists) 1.
Breast cancer risk: combined estrogen‑progestin regimens carry a higher breast cancer risk than estrogen alone (American College of Endocrinology & American Association of Clinical Endocrinologists) 2.

The recommendation to avoid estrogen therapy in smokers > 35 years is supported by Grade A evidence (BEL 1) from the American Association of Clinical Endocrinologists, concordant with FDA warnings and endorsed by multiple international guideline bodies (American College of Endocrinology & American Association of Clinical Endocrinologists) 1.